SEC Comment Letter for BIOSPECIFICS TECHNOLOGIES CORP (CIK 0000875622) — Apr 20, 2020
BIOSPECIFICS TECHNOLOGIES CORP (CIK 0000875622)
Date: April 20, 2020 · CIK: 0000875622 · Accession: 0000000000-20-003395
AI Filing Summary & Sentiment
File numbers found in text: 000-19879
Letter
April 20, 2020 J. Kevin Buchi Principal Executive Officer BioSpecifics Technologies Corp. 35 Wilbur Street Lynbrook, NY 11563 Re:BioSpecifics Technologies Corp. Preliminary Proxy Statement on Schedule 14A Filed April 17, 2020 File No. 000-19879 Dear Mr. Buchi: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carl A. Valenstein
Show Raw Text
April 20, 2020
J. Kevin Buchi
Principal Executive Officer
BioSpecifics Technologies Corp.
35 Wilbur Street
Lynbrook, NY 11563
Re:BioSpecifics Technologies Corp.
Preliminary Proxy Statement on Schedule 14A
Filed April 17, 2020
File No. 000-19879
Dear Mr. Buchi:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Carl A. Valenstein